Abstract
Circulating p53 antibodies (ELISA method), p53genetic alterations (SSCP), and protein overexpression(immunohistochemistry) were studied in 41 patients withcolorectal adenocarcinomas and 10 control patients. Carcinoembryonic antigen (CEA) and carbohydrateantigen 19.9 (CA 19-9) were evaluated in parallel. Tenpatients with p53 antibodies and p53 overexpression wereselected. Tumor DNA extracts from these 10 patients were analyzed by SSCP. Of all 41patients, 10 (24%) showed significant levels of p53antibodies, and p53 accumulation was detected in 20(48%) patients. In six patients, p53 antibodieconcentrations decreased rapidly after surgery; in twopatients, these levels returned to normal values. Of the10 selected tumors, eight revealed TP53 gene mutations.Only two patients with high values of both CEA and CA 19-9 developed p53 antibodies. Inconclusion, beside classical tumor markers, circulatingp53 antibodies may be considered as additional markersfor the management of patients with colorectaladenocarcinomas.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
REFERENCES
Greenblatt MS, Bennet WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cance r etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
Levine AJ, Perry ME, Chang A: The role of p53 tumoursuppressor gene in tumorigenesis. Br J Cance r 69:409-416, 1994
Soussi T, Legros Y, Lubin R, Ory K, Schlichtholtz B: Multifactorial analysis of p53 alteration in human cancer: A revie w. Int J Cance r 57:1-9, 1994
Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselin B, Remvikos Y: Association of p53 mutations with short survival in colorectal cancer. Gastroenterol 106:42-48, 1994
Bake r SJ, Fe aron ER, Nigro JM: Chromosome 17 deletions and p53 gene mutations in colore ctal carcinomas. Science 244:217-221, 1989
Porter PL, Gown AM, Kramp SG, Coltrera MD: Widespread p53 overexpre ssion in human malignant tumours. Am J Pathol 140:145-153, 1992
Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53produce a gene product that forms a hsp70-p53 complex with an altered half life. Mol Cell Biol 8:531-539, 1988
Schlichtholtz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo I, Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cance r Re s 52:6380- 6384, 1992
Labre cque S, Naor N, Thompson D, Matlashewski G: Analysis of the anti-p53 re sponse in cancer patients. Cance r Re s 53:3468-3471, 1993
Lubin R, Schlichtholz B, Te illaud JL, Garay E, Bussel A, Wild CP, Soussi T: p53 antibodies in patients with various types of cancer: Identification and characterizat ion. Clin Cancer Re s 1:1463-1469, 1995
Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cance rs. Proc Natl Acad Sci USA 89:3439-3442, 1992
Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Deve lopment of antibodies against p53 in lung cancer patients appe ars to be dependent on the type of p53 mutation. Cancer Re s 52:4168-4174, 1992
Müller M, Volkmann M, Zentgraf H, Galle P: Clinical implications of the p53 tumour-suppre ssor gene. N Engl J Med 330:865, 1994 (letter)
Campani D, Cecche tti D, Bevilacqua G: Immunocytochemical p53 detection by microwave oven heating of routinely formalin-fixed paraffin se ctions. J Pathol 171:151-152, 1993
Jiko K, Sasano H, Ito K, Ozawa N, Sato S, Yajima A: Immunohistochemical and in situ hybridization analysis of p53 in human endome trial carcinoma of the uterus. Anticance r Re s 13:305-310, 1993
Lassam NJ, From L, Kahn HJ: Overexpre ssion of p53 is a late eve nt in the deve lopment of malignant me lanoma. Cancer Res 53:2235-2238, 1993
Baas IO, Mulder JWR, Hofferhaus GJA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasm. J Pathol 172:5-12, 1994
Kre ssne r ULF, Lindmark G, Gerdin B, Pahlman L, Glimelius B: Immunohistochemical p53 staining is of limited value in the staging and pronostic prediction of colorectal cancer. Anticance r Re s 16:951-958, 1996
Hamme l P, Boissier B, Chaumette MT, Piebois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T: Detection and monitoring of serum p53 antibodies in patients with colorectal cance r. Gut 40:356-361, 1997
Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the ce llular protein p53 in the sera from patients with breast cancer. Int J Cancer 30:403-408, 1982
Volkmann M, Müller M, Hofmann J, Meye r M, Hagelste in J, Räth U, Komme re ll B, Zentgraf H, Galle PR: The humoral immune response to p53 in patients with hepatoce llular carcinoma is specific for malignancy and independent of the a-fetoprotein status. Hepatology 18:559-565, 1993
Angelopoulou K, Diamandis EP: Autoantibodies against the p53 tumour suppressor gene product quantified in cance r patient serum with time-resolved immunofluorometry. Cancer J 6:315-321, 1993
Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredanie l J, Hirsch A: Analysis of p53 antibodies in patients with various cancers define B-ce ll epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Re s 53:5872-5876, 1993
Mudenda B, Gre en JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinste r SJ: The re lationship between serum p53 autoantibodie s and characte ristics of human breast cance r. Br J Cancer 69:1115-1119, 1994
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associate d protein in human sarcomas. Nature 358:80-83, 1992
Barnes DM, Hanby AM, Gillett CE, Mohamed S, Hodgson S, Bobrow LG, Leigh IM, Purkis T, Mac Geoch C, Spurr NK, Bartek J, Vojtesek B, Pickseley M, Lane DP: Abnormal expression of wild type p53 protein in normal cells of a cance r family patient. Lance t 340:259-263, 1992
Hall PA, McKee PH, Du P, Menage H, Dover R, Lane DP: High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8:203-207, 1993
Preudhomme C, Lubin R, Lepelley P, Vanrumbe ke M, Fenaux P: Dete ction of serum anti-p53 antibodies and their corre lation with p53 mutations in mye lodysplastic syndromes and acute myeloid leukemia. Leukemia 8:1589-1591, 1994
Wild CP, Ridanpää M, Anttila S, Lubin S, Soussi T, Husgafve l-Pursiainen K, Vanino H: p53 antibodies in the se ra of lung cancer patients: Comparison with p53 mutations in the tumour tissue. Int J Cancer 64:176-181, 1995
Shibata Y, Kotanagi H, Andoh H, Koyama K, Itoh H, Kudo SE: Dete ction of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's re lation to clinical factors. Dis Colon Rectum 39:1269-1274, 1996
Hartmann A, Blaszyk H, McGovern RM, Schroede r JJ, Cunningham J, De Vries EMG: p53 gene mutations inside and outside of exons 5-8: The patterns differ in breast and other cancers. Oncogene 10:681-688, 1995
Bertorelle R, Esposito G, Be lluco C, Bonaldi L, Del Mistro A, Nitti D, Lise M, Chieco-Bianchi L: p53 gene alterations and protein accumulation in colore ctal cance r. J Clin Pathol Mol Pathol 49:M85-M90, 1996
Houbiers JGA, Van der Burg SH, Van de Wate ring LMG, Tollenaar RAEM, Brand A, Van de Ve lde CJH, Melief CJM: Antibodies against p53 are associated with poor prognosis of colorectal cance r. Br J Cancer 72:637-641, 1995
Rights and permissions
About this article
Cite this article
Polge, A., Bourgaux, JF., Bancel, E. et al. p53 and Follow-up of Colorectal Adenocarcinomas. Dig Dis Sci 43, 1434–1442 (1998). https://doi.org/10.1023/A:1018890126260
Issue Date:
DOI: https://doi.org/10.1023/A:1018890126260